BOSTON – The rise in the number of new drug approvals granted by the FDA in the past three years looks encouraging – hinting as it does that the industry is putting the productivity woes of the previous decade behind it. Read More

BOSTON – Recent advances in the tools and technology for drug discovery mean it now takes minutes and days to accomplish tasks that previously took months and weeks. Read More

LONDON – 2013 will be a watershed year for biosimilars – biological therapies designed to be similar to existing biological therapeutic agents – delegates attending the Second Biosimilars Congregation in London heard Tuesday. Read More

Following pressure from a group of dissident shareholders, Diamyd Medical AB agreed to return most of its cash to its investors, while retaining a small amount to continue two Phase II trials of its GAD vaccine for the treatment and prevention of Type I diabetes. Read More

The FDA accepted for review a new drug application for lixisenatide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist Zealand Pharma A/S has developed in partnership with Sanofi SA, paving the way for a possible U.S. approval in Type II diabetes by early 2014. Read More

BOSTON – Location, location, location: The idea that one gene equals one protein is long discredited and research into mechanisms including post-translational modification of proteins and the baroque complexities of epigenetic control is advancing understanding of how one gene can generate multiple proteins. Read More

• Dompe Group, of Milan, Italy, said the first patient has been enrolled in a Phase I/II REPARO study evaluating the ophthalmological use of a topical solution of recombinant human nerve growth factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK). Read More